shortness of breath tirzepatide GLP-1 and Breath: Causes and When to Seek Care Our next Misdiagnosis Monday -

Clinical trials of FDA-approved semaglutide and tirzepatide show the difference clearly: Semaglutide patients lose about 15% of total body weight Tirzepatide patients lose approximately 21% Both medications can cause mild gastrointestinal side effects, but tirzepatide is often better tolerated, with many patients reporting fewer symptoms

Weight plateaus are common after 11.5 years

The dismissal suggests the court did not find merit in the specific claims against Strive

It's FDA approved to manage diabetes and obesity

It says a qualified provider should review the full medication list, comorbidities, and recent labs first, and states directly that neither therapy should be self-initiated without medical clearance

Avoiding these pitfalls isn't hard